Healthy PeoplePhase 4NCT06730620
Bioequivalence Study of Methacholine Chloride
A Phase 4 study testing Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) in people with Healthy People, run by China-Japan Friendship Hospital at 1 site in China.
Trial summary
This trial was divided into two parts. The first part was the PK bioequivalence study in healthy people, which was designed as a single-dose, randomized, open, four-cycle, two-sequence, fully repeated crossover design, and planned to enroll 20 subjects. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy People
- What is being tested?
- Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 29 Jan 2024to 3 Feb 2024
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Inclusions Criteria
- Male or female healthy subjects aged 18 to 50 years old (including 18 and 50 years old).
- Male subjects weigh no less than 50 kg, female subjects weigh no less than 45 kg; and body mass index (BMI) = weight (kg) / height 2 (m2), and body mass index is within the range of 18.5~27.0 (including critical values).
- Normal pulmonary function test (FEV1 ≥ 80% predicted value, FEV1/FVC ≥ 0.7), FEV1 decline rate after inhalation of saline is no more than 20%, and methacholine chloride provocation test is negative.
- Sign the informed consent form before the experiment and fully understand the content, process and possible adverse reactions of the experiment.
- Subjects can communicate well with researchers and understand and comply with the requirements of this study.
Exclusions Criteria
- Ask for any diseases that might interfere with the test results
- Have a history of drug/food allergy
- blood collection difficulties or can not tolerate indwelling needle blood collection
- Patients who had surgery within 4 weeks prior to the trial or planned to have surgery during the study period
- Patients who have used any drug within 2 weeks before the test
- Subjects have participated in any drug or medical device clinical study within 3 months prior to screening (except those who failed screening or did not receive any experimental drug).
- Blood loss or blood donation exceeding 400 mL in the 3 months prior to screening (excluding female menstrual blood loss), or who intend to donate blood during the trial or within 1 month after the trial.
- pregnant and lactating women, or pregnancy test positive.
- Male subjects (or their partners) or female subjects had unprotected sex or had a pregnancy plan from 1 week before screening to 3 months after the end of the trial, and were unwilling to use one or more non-drug contraceptive methods (such as total abstinence, contraceptive rings, partner ligation, etc.) during the trial.
- Previous history of drug abuse/drug use; Or test positive for drug abuse.
- the diet has special requirements, can not comply with the unified diet.
- Those who had a smoking history within 6 months before the test, smoked more than 5 cigarettes per day, or were unwilling to give up smoking during the test, or had positive results of nicotine screening.
- Alcoholics or regular drinkers in the six months prior to the trial, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or breath-positive for alcohol.
- Eating a diet within 48 hours prior to taking the study drug that may affect the metabolism of the drug in the body, smoking, drinking behavior, or other diet that the investigator believes may affect the absorption, distribution, metabolism, or excretion of the drug.
- Physical examination, electrocardiogram, laboratory examination, vital signs and other tests related to the test were judged by the investigator to be abnormal and clinically significant.
- Acute illness or concomitant medication occurred from the screening stage to the study medication.
- Subjects who may not be able to complete the study for other reasons or who the investigator believes should not be included
Trial locations and contacts
1 site in 1 country.
China1 site
China-japan Friendship Hospital
Beijing, Beijing Municipality, 100029
About this study
Official title: Bioequivalence Study of Methacholine for Inhalation
This trial was divided into two parts. The first part was the PK bioequivalence study in healthy people, which was designed as a single-dose, randomized, open, four-cycle, two-sequence, fully repeated crossover design, and planned to enroll 20 subjects.
- Conditions
- Healthy People
- Being tested
- Test preparation:Methylcholine chloroacetate for inhalation, Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Test preparation:Methylcholine chloroacetate for inhalationDrug
Cholinergic agonists
Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)Drug
Cholinergic agonists
| Study group | Role | What they receive |
|---|---|---|
| Test preparation:Methylcholine chloroacetate for inhalation | Experimental | Inhale methacholine solution for 1 minute Receives: Drug: Test preparation:Methylcholine chloroacetate for inhalation |
| Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) | Active comparator | Inhale methacholine solution for 1 minute Receives: Drug: Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak Concentration
The highest plasma drug concentration that can be achieved after administration
Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
The area under the blood concentration time curve when the time is from 0 to the last time point selected(AUC0-t)
The area under the blood concentration time curve from 0 to t after administration
Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
The area under the blood concentration time curve during time from 0 to infinity(AUC0-∞)
Area under the blood concentration time curve after medication
Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2024
- Study start29 Jan 2024
- Primary completion3 Feb 2024
- Study completion3 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy PeopleStudies of the same condition, open and under way.
- More trials run by China-Japan Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- China-Japan Friendship Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Responsible party
- Principal investigator, Ting YANG, China-Japan Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06730620
- Sponsor's protocol ID
- TQC3610-BE-01
- Status last verified
- Dec 2024
- First submitted
- 30 Nov 2024
- Last updated
- 12 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioequivalence Study of Methacholine for Inhalation
- ClinicalTrials.gov ID
- NCT06730620
- Acronym / sponsor ID
- TQC3610-BE-01
- Conditions
- Healthy People
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- China-Japan Friendship HospitalUniversity, hospital or other
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Study start
- 29 Jan 2024 (actual)
- Primary completion
- 3 Feb 2024 (actual)
- Study completion
- 3 Feb 2024 (actual)
- First posted
- 12 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial was divided into two parts. The first part was the PK bioequivalence study in healthy people, which was designed as a single-dose, randomized, open, four-cycle, two-sequence, fully repeated crossover design, and planned to enroll 20 subjects.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test preparation:Methylcholine chloroacetate for inhalation | Experimental | Drug: Test preparation:Methylcholine chloroacetate for inhalationInhale methacholine solution for 1 minute |
| Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) | Active comparator | Drug: Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)Inhale methacholine solution for 1 minute |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Test preparation:Methylcholine chloroacetate for inhalationCholinergic agonists | Drug | Test preparation:Methylcholine chloroacetate for inhalation |
| Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)Cholinergic agonists | Drug | Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) |
Primary outcome
Peak Concentration
Time frame: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
The highest plasma drug concentration that can be achieved after administration
The area under the blood concentration time curve when the time is from 0 to the last time point selected(AUC0-t)
Time frame: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
The area under the blood concentration time curve from 0 to t after administration
The area under the blood concentration time curve during time from 0 to infinity(AUC0-∞)
Time frame: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration
Area under the blood concentration time curve after medication
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2024.
Related trials for Healthy People
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
RecruitingObservational study
Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy
Healthy Volunteer
Not yet recruitingPhase 1
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
Healthy
RecruitingPhase 1
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
Healthy
RecruitingPhase 1/2
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Herpes Zoster
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) in people with Healthy People, run by China-Japan Friendship Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak Concentration (time frame: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2024.